393 related articles for article (PubMed ID: 33364198)
1. Glioblastoma Organoids: Pre-Clinical Applications and Challenges in the Context of Immunotherapy.
Klein E; Hau AC; Oudin A; Golebiewska A; Niclou SP
Front Oncol; 2020; 10():604121. PubMed ID: 33364198
[TBL] [Abstract][Full Text] [Related]
2. Glioblastoma modeling with 3D organoids: progress and challenges.
Wang X; Sun Y; Zhang DY; Ming GL; Song H
Oxf Open Neurosci; 2023; 2():kvad008. PubMed ID: 38596241
[TBL] [Abstract][Full Text] [Related]
3. Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts.
Yabo YA; Moreno-Sanchez PM; Pires-Afonso Y; Kaoma T; Nosirov B; Scafidi A; Ermini L; Lipsa A; Oudin A; Kyriakis D; Grzyb K; Poovathingal SK; Poli A; Muller A; Toth R; Klink B; Berchem G; Berthold C; Hertel F; Mittelbronn M; Heiland DH; Skupin A; Nazarov PV; Niclou SP; Michelucci A; Golebiewska A
bioRxiv; 2023 Dec; ():. PubMed ID: 36945572
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional culture models to study glioblastoma - current trends and future perspectives.
Joseph JV; Blaavand MS; Daubon T; Kruyt FA; Thomsen MK
Curr Opin Pharmacol; 2021 Dec; 61():91-97. PubMed ID: 34656940
[TBL] [Abstract][Full Text] [Related]
5. Modeling Patient-Derived Glioblastoma with Cerebral Organoids.
Linkous A; Balamatsias D; Snuderl M; Edwards L; Miyaguchi K; Milner T; Reich B; Cohen-Gould L; Storaska A; Nakayama Y; Schenkein E; Singhania R; Cirigliano S; Magdeldin T; Lin Y; Nanjangud G; Chadalavada K; Pisapia D; Liston C; Fine HA
Cell Rep; 2019 Mar; 26(12):3203-3211.e5. PubMed ID: 30893594
[TBL] [Abstract][Full Text] [Related]
6. Development of glioblastoma organoids and their applications in personalized therapy.
Xu C; Yuan X; Hou P; Li Z; Wang C; Fang C; Tan Y
Cancer Biol Med; 2023 Jun; 20(5):353-68. PubMed ID: 37283493
[TBL] [Abstract][Full Text] [Related]
7. Organoid models of glioblastoma: advances, applications and challenges.
Zhang C; Jin M; Zhao J; Chen J; Jin W
Am J Cancer Res; 2020; 10(8):2242-2257. PubMed ID: 32905502
[TBL] [Abstract][Full Text] [Related]
8. Modeling glioblastoma invasion using human brain organoids and single-cell transcriptomics.
Krieger TG; Tirier SM; Park J; Jechow K; Eisemann T; Peterziel H; Angel P; Eils R; Conrad C
Neuro Oncol; 2020 Aug; 22(8):1138-1149. PubMed ID: 32297954
[TBL] [Abstract][Full Text] [Related]
9. Utility of the Cerebral Organoid Glioma 'GLICO' Model for Screening Applications.
Weth FR; Peng L; Paterson E; Tan ST; Gray C
Cells; 2022 Dec; 12(1):. PubMed ID: 36611949
[TBL] [Abstract][Full Text] [Related]
10. Applications of organoid technology to brain tumors.
Wen J; Liu F; Cheng Q; Weygant N; Liang X; Fan F; Li C; Zhang L; Liu Z
CNS Neurosci Ther; 2023 Oct; 29(10):2725-2743. PubMed ID: 37248629
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV2 entry factors are expressed in primary human glioblastoma and recapitulated in cerebral organoid models.
Suarez-Meade P; Watanabe F; Ruiz-Garcia H; Rafferty SB; Moniz-Garcia D; Schiapparelli PV; Jentoft ME; Imitola J; Quinones-Hinojosa A
J Neurooncol; 2023 Jan; 161(1):67-76. PubMed ID: 36595192
[TBL] [Abstract][Full Text] [Related]
12. A Novel Mice Model for Studying the Efficacy and IRAEs of Anti-CTLA4 Targeted Immunotherapy.
Xu S; Yan X; Dai G; Luo C
Front Oncol; 2021; 11():692403. PubMed ID: 34178691
[TBL] [Abstract][Full Text] [Related]
13. Protocol for derivation of organoids and patient-derived orthotopic xenografts from glioma patient tumors.
Oudin A; Baus V; Barthelemy V; Fabian C; Klein E; Dieterle M; Wantz M; Hau AC; Dording C; Bernard A; Michelucci A; Yabo YA; Kanli G; Keunen O; Bjerkvig R; Niclou SP; Golebiewska A
STAR Protoc; 2021 Jun; 2(2):100534. PubMed ID: 34027491
[TBL] [Abstract][Full Text] [Related]
14. Immunocompetent Mouse Models in the Search for Effective Immunotherapy in Glioblastoma.
Wouters R; Bevers S; Riva M; De Smet F; Coosemans A
Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33374542
[TBL] [Abstract][Full Text] [Related]
15. Organoid Models of Glioblastoma and Their Role in Drug Discovery.
Rybin MJ; Ivan ME; Ayad NG; Zeier Z
Front Cell Neurosci; 2021; 15():605255. PubMed ID: 33613198
[TBL] [Abstract][Full Text] [Related]
16. A novel integrated system using patient-derived glioma cerebral organoids and xenografts for disease modeling and drug screening.
Zhang L; Liu F; Weygant N; Zhang J; Hu P; Qin Z; Yang J; Cheng Q; Fan F; Zeng Y; Tang Y; Li Y; Tang A; He F; Peng J; Liao W; Hu Z; Li M; Liu Z
Cancer Lett; 2021 Mar; 500():87-97. PubMed ID: 33309780
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds.
Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R
Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932
[TBL] [Abstract][Full Text] [Related]
18. Combination immunotherapy strategies for glioblastoma.
Chan HY; Choi J; Jackson C; Lim M
J Neurooncol; 2021 Feb; 151(3):375-391. PubMed ID: 33611705
[TBL] [Abstract][Full Text] [Related]
19. Anti-glioblastoma activity of monensin and its analogs in an organoid model of cancer.
Urbaniak A; Reed MR; Heflin B; Gaydos J; Piña-Oviedo S; Jędrzejczyk M; Klejborowska G; Stępczyńska N; Chambers TC; Tackett AJ; Rodriguez A; Huczyński A; Eoff RL; MacNicol AM
Biomed Pharmacother; 2022 Sep; 153():113440. PubMed ID: 36076555
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional organoid culture unveils resistance to clinical therapies in adult and pediatric glioblastoma.
Sundar SJ; Shakya S; Barnett A; Wallace LC; Jeon H; Sloan A; Recinos V; Hubert CG
Transl Oncol; 2022 Jan; 15(1):101251. PubMed ID: 34700192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
